SIRIO Enhances Company Strategy with Addition of Lonza’s Sara Lesina

SIRIO is enhancing its strategy for small and medium nutrition brands as Lonza’s Sara Lesina joins as GM in Europe.

SIRIO Pharma (SIRIO), a global nutraceutical contract development and manufacturing organization (CDMO), announced on Sept. 9, 2022 that it has appointed Sara Lesina as a new general manager in Europe. Lesina will seek to drive forward a strategy of targeting small and medium brands launching novel nutraceutical formulations.

Lesina previously worked at Lonza as executive director. According to a company press release, Lonza appointed Lesina to further its goal of nurturing new partnerships with large nutrition brands across the major European markets.

“I joined SIRIO because I see the tremendous resources it has – SIRIO has over 200 R&D scientists across its sites – and there are clear synergies with like-minded innovation focused customers,” commented Lesina in the press release. “We anticipate significant growth in the nutra market in next few years as customers see the benefits of working with an agile CDMO partner to help launch products to market faster. The SIRIO value proposition anchored on R&D and formulation capabilities, combined with our global manufacturing footprint, positions us well to tap into this growth by launching new products for customers.”

“Sara brings with her a tremendous global network and what impressed us is the clarity of purpose to establish SIRIO as the contract research and development hub for the most ambitious global brands,” added Rui Yang, vice-president at SIRIO. “Across Europe there is an increasing number of companies launching new products that could reduce their time to market and/or acquisition by working with SIRIO. Sara’s remit will be to help develop locally relevant formulatory options, working as the European conduit to access SIRIO’s global R&D resources.”

Source: SIRIO